If I'd invested $1,000 in CSL shares 24 years ago, here's how much I'd have now!

While some companies have lost value or even collapsed since listing, you might be surprised how many ASX 200 shares have rocketed over the long term.

CSL Ltd (ASX: CSL) shares first listed on the ASX way back on 8 June 1994.

The S&P/ASX 200 Index biotechnology company floated for $2.30 per share. But once we take share buybacks into account, the adjusted entry price works out to around 76 cents per share.

We won't go back quite that far.

But here's how much I'd have now if I'd invested $1,000 in CSL shares 24 years ago.

Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

Invest in CSL shares like it's 1999

Investing with perfect hindsight is a wonderful thing.

While some companies have lost value or even collapsed since listing, you might be surprised how many ASX 200 shares have rocketed over the long term.

CSL shares certainly count among the winners.

Back on 16 April 1999, CSL closed the day trading for $4.23 per share.

That means I could have bought 236 shares with my $1,000 and had enough left over for a cup of 1999-priced coffee.

At the time of writing, CSL is trading for $304.31 per share.

If I opted to sell those 236 shares today they'd get me a whopping $71,817 and change.

In other words, the stock would have seen me gain 7,081% on my initial investment over 24 years, from share price appreciation alone.

Don't forget the dividends!

But let's not forget that CSL shares also have a lengthy track record of delivering dividends.

According to my calculations, the biotech company has paid out approximately $28 per share in dividends since April 1999. That's more than six times what I would have paid for those shares in 1999.

Assuming I didn't reinvest those dividends but simply tucked the cash under my mattress for a rainy day, I'd have earned some $6,608 in passive income from my 236 shares.

Adding that in, my total gains on that $1,000 investment in 1999 have leapt to an eye-popping 7,742%.

Granted, inflation over that period will have cut those gains roughly in half in real terms.

But still, try getting that kind of yield from your bank!

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »